A Delaware federal judge has ruled four patents held by Teva Pharmaceuticals invalid as obvious, potentially clearing a path for competitors to bring generic versions of the company’s multiple sclerosis drug to market.
The ruling, announced late Monday, calls into question the future of the Israeli pharmaceutical giant’s 40-milligram injectable dose of Copaxone, the company’s top-selling drug, and it represented a clear win for Mylan Pharmaceuticals, Amneal Pharmaceuticals and three other drugmakers that have applied to market generic alternatives.
